{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:58:00Z","timestamp":1782471480921,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.rmed.2017.08.002","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T21:15:13Z","timestamp":1501794913000},"page":"43-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis"],"prefix":"10.1016","volume":"131","author":[{"given":"Shinhee","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Wook","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Do","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Sun","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2017.08.002_bib1","unstructured":"World Health Organization (WHO), Global tuberculosis report 2015, http:\/\/www.who.int\/tb\/publications\/global_report\/en\/(accessed 17.03.19)."},{"key":"10.1016\/j.rmed.2017.08.002_bib2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5588\/ijtld.11.0116","article-title":"Rise in rifampicin-monoresistant tuberculosis in western cape, South Africa","volume":"16","author":"Mukinda","year":"2012","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.rmed.2017.08.002_bib3","first-page":"571","article-title":"Trend of anti-tuberculosis drug resistance in Korea, 1994-2004","volume":"11","author":"Bai","year":"2007","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.rmed.2017.08.002_bib4","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3201\/eid1205.041339","article-title":"Mycobacterium tuberculosis and rifampin resistance, United Kingdom","volume":"12","author":"Sam","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.rmed.2017.08.002_bib5","doi-asserted-by":"crossref","first-page":"e0152933","DOI":"10.1371\/journal.pone.0152933","article-title":"Prevalence, risk factors, and treatment outcomes of isoniazid- and rifampicin-mono-resistant pulmonary tuberculosis in Lima, Peru","volume":"11","author":"Villegas","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.rmed.2017.08.002_bib6","series-title":"Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-resistant Tuberculosis","year":"2014"},{"key":"10.1016\/j.rmed.2017.08.002_bib7","series-title":"Guidelines for the Clinical and Operational Management of Drug-resistant Tuberculosis","author":"Caminero","year":"2013"},{"key":"10.1016\/j.rmed.2017.08.002_bib8","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1056\/NEJMra1413919","article-title":"Treatment of tuberculosis","volume":"373","author":"Horsburgh","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.rmed.2017.08.002_bib9","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1164\/ajrccm.159.2.9805097","article-title":"Risk factors for rifampin-monoresistant tuberculosis: a case-control study","volume":"159","author":"Sandman","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2017.08.002_bib10","first-page":"178","article-title":"Rifampicin mono-resistant Mycobacterium tuberculosis in Bujumbura, Burundi: results of a drug resistance survey","volume":"10","author":"Sanders","year":"2006","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.rmed.2017.08.002_bib11","doi-asserted-by":"crossref","first-page":"e77712","DOI":"10.1371\/journal.pone.0077712","article-title":"Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region","volume":"8","author":"Coovadia","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.rmed.2017.08.002_bib12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2334-14-18","article-title":"Rifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysis","volume":"14","author":"Meyssonnier","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.rmed.2017.08.002_bib13","doi-asserted-by":"crossref","first-page":"866","DOI":"10.5588\/ijtld.16.0034","article-title":"Treatment regimens for rifampicin-resistant tuberculosis: highlighting a research gap","volume":"20","author":"Stagg","year":"2016","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.rmed.2017.08.002_bib14","series-title":"Definitions and Reporting Framework for Tuberculosis\u20132013 Revision","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.rmed.2017.08.002_bib15","series-title":"Diagnostic Standards and Classification of Tuberculosis","author":"National Tuberculosis Association","year":"1961"},{"key":"10.1016\/j.rmed.2017.08.002_bib16","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1183\/09031936.96.09102026","article-title":"Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis","volume":"9","author":"Schaberg","year":"1996","journal-title":"Eur. Resp. J."},{"key":"10.1016\/j.rmed.2017.08.002_bib17","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","article-title":"Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients","volume":"18","author":"Aung","year":"2014","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.rmed.2017.08.002_bib18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5588\/ijtld.14.0535","article-title":"High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon","volume":"19","author":"Kuaban","year":"2015","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.rmed.2017.08.002_bib19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.5588\/ijtld.11.0360","article-title":"Rifampicin-monoresistant Mycobacterium tuberculosis disease among children in Cape Town, South Africa","volume":"16","author":"Dramowski","year":"2012","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.rmed.2017.08.002_bib20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4046\/trd.2009.66.5.349","article-title":"A\u00a0public-private collaboration model for treatment intervention to improve outcomes in patients with tuberculosis in the private sector","volume":"66","author":"Kim","year":"2009","journal-title":"Tuberc. Respir. Dis."},{"key":"10.1016\/j.rmed.2017.08.002_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4046\/trd.2011.70.2.143","article-title":"Increasing the treatment success rate of tuberculosis in a private hospital through public-private mix (PPM) project","volume":"70","author":"Park","year":"2011","journal-title":"Tuberc. Respir. Dis."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611117302652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611117302652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:36:53Z","timestamp":1760614613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611117302652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":21,"alternative-id":["S0954611117302652"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2017.08.002","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2017.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}